Lovastatin is a cholesterol lowering drug and competitive inhibitor of HMG-CoA reductase, a rate limiting enzyme in cholesterol synthesis. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. It increases cellular resistance to anticancer agents such as doxorubicin and induces apoptosis in myeloma cells. It causes cell cycle arrest in G1 and G2/M phases.
Jonathan A.Tobert. Efficacy and long-term adverse effect pattern of lovastatin. The American Journal of Cardiology. 1988, 62, (15),J28-J34
Peter Jones MD; Stephanie Kafonek MD; Irene Laurora PharmD; Donald Hunninghake MD. Comparative Dose Efficacy Study of Atorvastatin VersusSimvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study). The American Journal of Cardiology. 1998, 81, (5),582-587
Indicaciones de peligro (UE): H302-H315-H319-H335
Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.
Indicaciones de precaución: P261-P280a-P305+P351+P338-P304+P340-P405-P501a
Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves and eye/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.